This page is the continuation of references in support of Section 6E
REFERENCES
Brambilla E, Travis WD, Colby TV et al. (2001). The new World Health Organization classification of lung tumours. Eur Respir J 18, 1059–1068. (Retrieved 5th Feb 2015): ttp://erj.ersjournals.com/content/18/6/1059.long
Chu P, Wu E, Weiss LM. (2000) Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases. Mod Pathol;13(9):962–972. (Retrieved 28th April 2015): http://www.nature.com/modpathol/journal/v13/n9/full/3880175a.html
Conklin, C.M., Craddock, K.J., Have, C., Laskin, J., Couture, C. & Ionescu, D.N. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J. Thorac. Oncol. 8, 45–51 (2013). (Retrieved 19th Feb 2015): http://www.ncbi.nlm.nih.gov/pubmed/23196275?dopt=Abstract&holding=npg
Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV. et al. (2002) p63 Expression Profiles in Human Normal and Tumor Tissues. Clin Cancer Res February 8;494 (Retrieved 28th April 2015): https://www.ncbi.nlm.nih.gov/pubmed/11839669
Gately K, O’Flaherty J, Cappuzzo F, Pirker R, Kerr K, O’Byrne K. (2012). The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. J Clin Pathol 65(1), 1-7. (Retrieved 19th Feb 2015): https://www.ncbi.nlm.nih.gov/pubmed/22039281
Goldstein, N.S., Hewitt, S.M., Taylor, C.R., et al. (2007). Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol 15, 124–33. (Retrieved 19th Feb 2015): http://www.ncbi.nlm.nih.gov/pubmed/17525622?dopt=Abstract
Jagirdar J. (2008) Application of Immunohistochemistry to the Diagnosis of Primary and Metastatic Carcinoma to the Lung. Arch Pathol Lab Med 132(3) 384-396. (Retrieved 19th Feb 2015)
Ordóñez NG (2006) The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol.Mar;19(3):417-28. (Retrieved 28th April 2015): http://www.ncbi.nlm.nih.gov/pubmed/16415794
Pirker R, Herth FJ, Kerr KM, et al, (2010). European EGFR Workshop Group Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 5(10), 1706-13. (Retrieved 19th Feb 2015): http://www.ncbi.nlm.nih.gov/pubmed?term=20871269
Selinger CI, Rogers T-M, Russell PA et al. (2013). Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod. Pathol 26, 1545–1553. (Retrieved 19th Feb 2015): http://www.nature.com/modpathol/journal/v26/n12/full/modpathol201387a.html
Yatabe Y, Mitsudomi T, Takahashi T. (2002). TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 26, 767-73. (Retrieved 19th Feb 2015): http://www.ncbi.nlm.nih.gov/pubmed/12023581
